Newsmeme!
Discover News you didn't know existed
LDL Cholesterol
News
Related Video News
No related video news stories found.
Related Videos
No related videos found.
Another Downer For Merck's Cholesterol Drugs
Published July 9, 2009, 9:49 pm, Forbes
Why investors are right to worry that a new study could damage the company's outlook.
Healthbeat Report: Cholesterol filtering
Published July 9, 2009, 9:17 pm, ABC 7 Chicago
Find out about an alternative treatment for high cholesterol.
Blood vessel bends and branches put the brakes on statins
Published July 9, 2009, 4:00 pm, PRWeb via Yahoo! News
First evidence that biomechanical forces may affect drug's action.
Merck Falls After Study of Cholesterol Drugs Halted (Update3)
Published July 9, 2009, 2:29 pm, Bloomberg
July 9 (Bloomberg) -- Merck & Co. fell in New York trading after researchers halted a study comparing Abbott Laboratories ’ cholesterol drug Niaspan with Zetia, sold by Merck and Schering- Plough Corp .
(AFX UK Focus) 2009-07-09 20:44 UPDATE 3-Merck shares fall on cholesterol study concerns
Published July 9, 2009, 1:07 pm, Interactive Investor
By Lewis Krauskopf
(AFX UK Focus) 2009-07-09 20:32 UPDATE 3-Merck shares fall on cholesterol study concerns
Published July 9, 2009, 12:52 pm, Interactive Investor
By Lewis Krauskopf
Merck Falls After Study of Cholesterol Drugs Halted (Update2)
Published July 9, 2009, 11:13 am, Bloomberg
July 9 (Bloomberg) -- Merck & Co. fell the most in almost three months in New York trading after a study was halted comparing Abbott Laboratories ’ cholesterol drug Niaspan with Zetia, sold by Merck and Schering-Plough Corp .
Aetna Pilot Helps Physicians Improve Care For Diabetics
Published July 9, 2009, 10:14 am, Medical News Today
Aetna (NYSE: AET) and Total Therapeutic Management (TTM) announced the results of a pilot program in Southeastern Pennsylvania and South Florida that improved patient care and increased the number of physicians recognized by the National Committee for Quality Assurance (NCQA) Diabetes Physician Recognition Program. Funded by Amylin Pharmaceuticals, Inc.
Abbott Study of Niaspan Against Merck’s Zetia Halted (Update1)
Published July 9, 2009, 8:30 am, Bloomberg
July 9 (Bloomberg) -- A study comparing Abbott Laboratories ’ cholesterol drug Niaspan with Merck & Co. and Schering-Plough Corp.’s Zetia was ended early, for reasons unrelated to patients’ safety.
Amarin Receives Special Protocol Assessment Agreement from the FDA for Phase 3 Trial in Mixed Dyslipidemia
Published July 9, 2009, 5:42 am, Business Wire via Yahoo! Finance
DUBLIN----Amarin Corporation plc today announced that it has reached agreement with the U.S. Food and Drug Administration under a Special Protocol Assessment for its planned Phase 3 clinical trial of AMR101 in patients with mixed dyslipidemia.
Related News Resources:
> HGH News
News Directory
Get started fast by using a pre-defined news directory category
|
Breaking News
and Top Stories |
Business
Earnings, Economy, Personal Finance, and Stock Markets |
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre |
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss |
Politics
Congress, Supreme Court, and White House |
|
Science
Animals, Astronomy, Biotechnology, Space, and Weather |
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis |
Technology
Communications, Hardware, Internet, Personal Technology, and Software |
United States
and Crimes and Trials |
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East |